Issue Archive

Therapeutic potential of targeting SIRT1 for the treatment of Alzheimer’s disease

SHEN Li-Li¹, SUN Hui-Yan^2,3, WANG Hong-Quan^4,*

¹Department of Neurology, The Affiliated Hospital of Chifeng University, Chifeng 024005, China；²Chifeng University Health Science Center, Chifeng 024000, China；³Key Laboratory of Human Genetic Diseases in Inner Mongolia, Chifeng 024000, China；⁴Department of Neurology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing 100049, China

Abstract

Silent information regulator 1 (SIRT1) is one of the seven mammalian proteins of the sirtuin family of NAD+-dependent deacetylases. SIRT1 plays a pivotal role in neuroprotection and ongoing research has uncovered a mechanism by which SIRT1 may exert a neuroprotective effect on Alzheimer’s disease (AD). Growing evidence demonstrates that SIRT1 regulates many pathological processes including amyloid-β precursor protein (APP) processing, neuroinflammation, neurodegeneration, and mitochondrial dysfunction. SIRT1 has recently received enormous attention, and pharmacological or transgenic approaches to activate the sirtuin pathway have shown promising results in the experimental models of AD. In the present review, we delineate the role of SIRT1 in AD from a disease- centered perspective and provides an up-to-date overview of the SIRT1 modulators and their potential as effective therapeutics in AD.

Key words: Alzheimer’s disease; deacetylases; SIRT1; SIRT1 activator

Received: 　　Accepted:

Corresponding author: 王洪权　　E-mail:

DOI: 10.13294/j.aps.2023.0007

Citing This Article：

SHEN Li-Li, SUN Hui-Yan, WANG Hong-Quan. Therapeutic potential of targeting SIRT1 for the treatment of Alzheimer’s disease. Acta Physiol Sin 2023; 75 (1): 99-107 (in Chinese with English abstract).